Steven Lo Biography and Net Worth

CEO of Vaxart

Mr. Lo is a highly experienced biopharma executive with over 25 years of experience in the healthcare, biotechnology, and pharmaceutical industries, including over 12 years of C-level experience in publicly traded biotech companies.

Prior to Vaxart, Mr. Lo was Chief Executive Officer and a member of the board of directors of Valitor, a private biotech company, from 2022 to 2024. From 2019 to 2022, he was the President, Chief Executive Officer, and member of the board of directors of Zosano Pharma. From 2015 to 2019, he was the Chief Commercial Officer at Puma Biotechnology. At that company, he built and led business development and the worldwide commercialization of the company’s first product. Prior to that, he was Chief Commercial Officer of Corcept Therapeutics, where he established the commercial organization to launch the company’s first product. Earlier in his career, he spent 13 years at Genentech in a variety of leadership roles in commercialization and market access.

Mr. Lo obtained a master’s in Health Administration from the University of Southern California and a B.S. in Microbiology from the University of California, Davis.

What is Steven Lo's net worth?: The estimated net worth of Steven Lo is at least $50.33 thousand as of May 19th, 2025. Mr. Lo owns 100,000 shares of Vaxart stock worth more than $50,330 as of August 28th. This net worth estimate does not reflect any other investments that Mr. Lo may own. Learn More about Steven Lo's net worth.
How do I contact Steven Lo?: The corporate mailing address for Mr. Lo and other Vaxart executives is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. Vaxart can also be reached via phone at (650) 550-3500 and via email at [email protected]. Learn More on Steven Lo's contact information.
Has Steven Lo been buying or selling shares of Vaxart?: Steven Lo has not been actively trading shares of Vaxart during the past quarter. Most recently, on Monday, May 19th, Steven Lo bought 100,000 shares of Vaxart stock. The stock was acquired at an average cost of $0.49 per share, with a total value of $49,000.00. Following the completion of the transaction, the insider now directly owns 100,000 shares of the company's stock, valued at $49,000. Learn More on Steven Lo's trading history.
Who are Vaxart's active insiders?: Vaxart's insider roster includes Margaret Echerd (SVP), Wouter Latour (Director), Steven Lo (CEO), and Sean Tucker (SVP). Learn More on Vaxart's active insiders.

Steven Lo Insider Trading History at Vaxart

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/19/2025	Buy	100,000	$0.49	$49,000.00	100,000

Steven Lo Buying and Selling Activity at Vaxart

Vaxart Company Overview

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Today's Range

Now: $0.50

$0.49

$0.51

50 Day Range

MA: $0.54

$0.45

$0.64

2 Week Range

Now: $0.50

$0.31

$0.84

Volume

554,436 shs

Average Volume

278,202 shs

Market Capitalization

$122.40 million

P/E Ratio

3.15

Dividend Yield

N/A

Beta

1.1